Risperidone long-acting injection (RLAI): The 12-week efficacy and tolerability in thai patients with chronic schizophrenia
Background: Although oral atypical antipsychotics have improved the outcomes in schizophrenia, the patient medication adherence plays role as the important factor to clinical potential of the drugs. Therefore, the long-acting formulations of antipsychotics have been developed to improve the treatmen...
Saved in:
Main Authors: | Arunpongpaisal S., Srisurapanont M., Kongsakon R., Kitiwattanagul K., Samanwongthai U. |
---|---|
Format: | Journal |
Published: |
2017
|
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77951895519&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/43339 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Risperidone long-acting injection (RLAI): The 12-week efficacy and tolerability in thai patients with chronic schizophrenia
by: Suwanna Arunpongpaisal, et al.
Published: (2018) -
Risperidone long-acting injection (RLAI): The 12-week efficacy and tolerability in thai patients with chronic schizophrenia
by: Suwanna Arunpongpaisal, et al.
Published: (2018) -
Cost analysis of the treatment of schizophrenia in Thailand: A simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol
by: Ronnachai Kongsakon, et al.
Published: (2018) -
The impact of adjunctive aripiprazole on QT interval: a 12-week open label study in patients on olanzapine, clozapine or risperidone
by: Pilunthanakul, Thanita, et al.
Published: (2023) -
Efficacy of risperidone for prevention of postoperative delirium in cardiac surgery
by: U. Prakanrattana, et al.
Published: (2018)